ENHANCED ANTICONVULSANT EFFICACY OF INTERLEUKIN RECEPTOR BLOCKADE FOLLOWING LEVETIRACETAM USE

Authors:

Abstract:

The purpose of the study was to determine the principal possibility of enhancement of the anticonvulsant effect of interleukin receptor blockade by levetiracetam in chronic experimental epileptogenesis. Experimental studies were performed on models of acute generalized and chronic epileptic activity. Rats were treated with systemic and intracerebroventricular injections of a recombinant interleukin receptor blocker, administered in combination with levetiracetam. Interleukin receptor activity block was shown to protect animals from acute generalized and chronic seizures during kindling and postkindling. The revealed recombinant interleukin receptor antagonist, when administered systemically and intracerebroventricularly, shows anticonvulsant efficacy that is enhanced by levetiracetam. The revealed anticonvulsant effect is observed in acute generalized pentylenetetrazole- and kainic acid-induced seizures, as well as in a chronic convulsive syndrome under intra-hippocampal blockade of interleukin receptors. The obtained results indicate that the inflammatory response is involved in the pathogenetic mechanisms of seizure syndrome. The author concludes that the fundamental possibility of increasing anticonvulsant therapy efficacy in patients with refractory epilepsy was achieved through the co-administration of drugs that block neurotransmitter systems responsible for the initiation and propagation of excessive bioelectrical activity.

Keywords:

convulsive syndrome kindling postkindling cytokines recombinant antagonist of interleukin-1 receptors levetiracetam neurotransmitter systems pathogenetic mechanisms

References:

1. Boleti ApdA, Cardoso PhdO, Frihling BEF, de Moraes LFRN, Nunes EAC, Mukoyama LTH. et al. Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy. Brain Sci. 2024; 14: 71. doi: 10.3390/brainsci14010071.
2. Flammer J, Neziraj T, Rüegg S, Pröbstel AK. Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes. Drugs. 2023; 83(2): 135-158. doi: 10.1007/s40265-022-01826-9.
3. Godlevsky LS, Alkan I, Tüfekci KK, Pervak MP, Kaplan S. Different mechanisms of axitinib and diazepam antiseizure action in pentylenetetrazol-induced kindling model. IBRO Neuroscience Reports. 2025; 19: 668-678. doi: 10.1016/j.ibneur.2025.09.005.
4. Hanaya R, Arita K. The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications. Neurol Med Chir (Tokyo). 2016; 56(5): 205-220. doi: 10.2176/nmc.ra.2015-0344.
5. Kobylarek D, Iwanowski P, Lewandowska Z, Limphaibool N, Szafranek S, Labrzycka A. et al. Advances in the Potential Biomarkers of Epilepsy. Front Neurol. 2019; 10: 685. doi: 10.3389/fneur.2019.00685.
6. Kozlowski P, Czepińska-Ćwik W, Kozlowska M, Kozlowska K. Levetiracetam-epilepsy treatment, pharmacokinetics, mechanism of action, interaction and toxicity. Journal of Education, Health and Sport. 2015; 5 (4): 143-150. doi: 10.5281/zenodo.16694.
7. Ostapenko IO. Impact of vortioxetine with antiepileptic drugs combined administration on non-convulsive behaviour in kindled rats. Journal of Education, Health and Sport. 2023; 13 (3): 432-441. doi 10.12775/JEHS.2023.13.03.053.
8. Paudel YN, Shaikh MF, Shah S, Kumari Y, Othman I. Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy. Eur J Pharmacol. 2018; 837: 145-155. doi: 10.1016/j.ejphar.2018.08.020.
9. Poshyvak O, Pinyazhko O, Godlevsky L, Pervak M, Yehorenko O, Doganyigit Z. et al. Immunohistochemical neuroinflammatory markers in the hippocampus of PTZ-kindled rats under conditions of rapamycin and axitinib treatment. ScienceRise: Pharmaceutical Science. 2023; 1(41): 23–31. doi: http://doi.org/10.15587/2519-4852.2023.274468.
10. Ravizza T, Vezzani A. Pharmacological targeting of brain inflammation in epilepsy: Therapeutic perspectives from experimental and clinical studies. Epilepsia Open. 2018; 3 (Suppl Suppl 2): 133-142. doi: 10.1002/epi4.12242.
11. Shampa G, Jitendra KS, Tarab K, Kuramkote SD, Prabhakar S, Kumar V. et al. Pharmacological and Therapeutic Approaches in the Treatment of Epilepsy. Biomedicines. 2021; 9(5): 470. doi: 10.3390/biomedicines9050470.
12. Snellman A, Tuisku J, Koivumäki M, Wahlroos S, Aarnio R, Rajander J. et al. SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes. Alzheimers Dement. 2024; 20(12): 8802-8813. doi: 10.1002/alz.14327.
13. Vastyanov RS, Stoyanov AN, Krepec YuS, Dzygal AF, Beseda YaV, Puchkova AV. Interleukin-1 receptors antagonist intracerebral administrations anticonvulsive efficacy in conditions of kindling model of epileptogenesis. World of Medicine and Biology. 2020; 4(74): 168-174. doi: 10.26724/2079-8334-2020-4-74-168-174.
14. Vezzani AM. Epilepsy and Inflammation in the Brain: Overview and Pathophysiology. Epilepsy Curr. 2014; 14 (1 Suppl): 3–7. doi: 10.5698/1535-7511-14.s2.3.
15. Wirrell EC, Nabbout R, Scheffer IE, Alsaadi T, Bogacz A, French JA. et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022; 63(6): 1333-1348. doi: 10.1111/epi.17237.

Publication:

«World of Medicine and Biology» Vol. 21 No. 94 (2025) , с. 161-166
УДК 612.017.1:612.8.062;612.821.7+616.853

DOI:

https://doi.org/10.26724/2079-8334-2025-4-94-161-166